YS Biopharma Co., Ltd. announced that it has entered into a share purchase agreement with an institutional investor to issue 95,269,762 ordinary shares at an issue price of $0.41986 per Share for the gross proceeds of $39,999,962.27332 on February 9, 2024.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9765 USD | -0.14% | +8.49% | +91.10% |
04-19 | YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023 | CI |
04-18 | YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.10% | 184M | |
-3.05% | 90.45B | |
+3.95% | 41.45B | |
-10.57% | 33.57B | |
+60.58% | 25.73B | |
-20.68% | 14.73B | |
-9.17% | 12.82B | |
-11.46% | 11.7B | |
-43.05% | 11.44B | |
+5.17% | 8.79B |
- Stock Market
- Equities
- YS Stock
- News YS Biopharma Co., Ltd.
- YS Biopharma Co., Ltd. announced that it expects to receive $39.999962 million in funding